{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:28:45Z","timestamp":1790180925635,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Medical and Health Science and Technology Project","award":["2024KY784"],"award-info":[{"award-number":["2024KY784"]}]},{"name":"Zhejiang Provincial Medical and Health Science and Technology Project","award":["No.2024KY785"],"award-info":[{"award-number":["No.2024KY785"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81702248"],"award-info":[{"award-number":["81702248"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-20263-8","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:38:31Z","timestamp":1760711911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TET2 repression contributes to EGFR TKI resistance in EGFR-mutant non-small cell lung cancer through regulating AXIN2 methylation"],"prefix":"10.1038","volume":"15","author":[{"given":"Hangjie","family":"Ying","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"10026","key":"20263_CR1","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","volume":"387","author":"F Barlesi","year":"2016","unstructured":"Barlesi, F. et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet 387 (10026), 1415\u20131426 (2016).","journal-title":"Lancet"},{"issue":"3","key":"20263_CR2","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/cancers7030864","volume":"7","author":"V Boolell","year":"2015","unstructured":"Boolell, V., Alamgeer, M., Watkins, D. N. & Ganju, V. The evolution of therapies in Non-Small cell lung cancer. Cancers (Basel). 7 (3), 1815\u20131846. https:\/\/doi.org\/10.3390\/cancers7030864 (2015).","journal-title":"Cancers (Basel)"},{"issue":"suppl_1","key":"20263_CR3","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu, W. H., Yang, J. C., Mok, T. S. & Loong, H. H. Overview of current systemic management of EGFR-mutant NSCLC. Ann. Oncol. 29 (suppl_1), i3\u2013i9 (2018).","journal-title":"Ann. Oncol."},{"issue":"75","key":"20263_CR4","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl Med. 3 (75), 75ra26 (2011).","journal-title":"Sci. Transl Med."},{"issue":"12","key":"20263_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"JC Yang","year":"2017","unstructured":"Yang, J. C. et al. Osimertinib in pretreated T790M-Positive advanced Non-Small-Cell lung cancer: AURA study phase II extension component. J. Clin. Oncol. 35 (12), 1288\u20131296 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"20263_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl. J. Med. 382 (1), 41\u201350 (2020).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"20263_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","volume":"14","author":"BC Cho","year":"2019","unstructured":"Cho, B. C. et al. Osimertinib versus standard of care EGFR TKI as First-Line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J. Thorac. Oncol. 14 (1), 99\u2013106 (2019).","journal-title":"J. Thorac. Oncol."},{"issue":"25","key":"20263_CR8","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2217\/fon-2019-0346","volume":"15","author":"MJ Hochmair","year":"2019","unstructured":"Hochmair, M. J. et al. Sequential Afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 15 (25), 2905\u20132914 (2019).","journal-title":"Future Oncol."},{"issue":"8","key":"20263_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaoncol.2018.1395","volume":"4","author":"PN Aguiar Jr","year":"2018","unstructured":"Aguiar, P. N. Jr. et al. Cost-effectiveness of osimertinib in the First-Line treatment of patients with EGFR-Mutated advanced Non-Small cell lung cancer. JAMA Oncol. 4 (8), 1080\u20131084 (2018).","journal-title":"JAMA Oncol."},{"issue":"5","key":"20263_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1517\/14740338.2014.904283","volume":"13","author":"E Lucchini","year":"2014","unstructured":"Lucchini, E. et al. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opin. Drug Saf. 13 (5), 535\u2013549 (2014).","journal-title":"Expert Opin. Drug Saf."},{"key":"20263_CR11","doi-asserted-by":"publisher","first-page":"175883591989028","DOI":"10.1177\/1758835919890286","volume":"11","author":"BC Liao","year":"2019","unstructured":"Liao, B. C., Griesing, S. & Yang, J. C. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther. Adv. Med. Oncol. 11, 1758835919890286 (2019).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"20263_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-319-43139-0_5","volume":"943","author":"M Le Gallo","year":"2017","unstructured":"Le Gallo, M., Lozy, F. & Bell, D. W. Next-Generation sequencing. Adv. Exp. Med. Biol. 943, 119\u2013148 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"issue":"38","key":"20263_CR13","doi-asserted-by":"publisher","first-page":"61755","DOI":"10.18632\/oncotarget.11237","volume":"7","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget 7 (38), 61755\u201361763 (2016).","journal-title":"Oncotarget"},{"issue":"1","key":"20263_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20 (1), 11\u201324 (2011).","journal-title":"Cancer Cell."},{"issue":"15","key":"20263_CR15","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/onc.2016.376","volume":"36","author":"ML Nickerson","year":"2017","unstructured":"Nickerson, M. L. et al. TET2 binds the androgen receptor and loss is associated with prostate cancer. Oncogene 36 (15), 2172\u20132183 (2017).","journal-title":"Oncogene"},{"issue":"11","key":"20263_CR16","doi-asserted-by":"publisher","first-page":"eaau6986","DOI":"10.1126\/sciadv.aau6986","volume":"4","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. TET2 coactivates gene expression through demethylation of enhancers. Sci. Adv. 4 (11), eaau6986 (2018).","journal-title":"Sci. Adv."},{"key":"20263_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","volume":"70","author":"M Kulis","year":"2010","unstructured":"Kulis, M. & Esteller, M. DNA methylation and cancer. Adv. Genet. 70, 27\u201356 (2010).","journal-title":"Adv. Genet."},{"issue":"1","key":"20263_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","volume":"153","author":"H Shen","year":"2013","unstructured":"Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153 (1), 38\u201355 (2013).","journal-title":"Cell"},{"issue":"3","key":"20263_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nm.2305","volume":"17","author":"M Rodriguez-Paredes","year":"2011","unstructured":"Rodriguez-Paredes, M. & Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17 (3), 330\u2013339 (2011).","journal-title":"Nat. Med."},{"issue":"1","key":"20263_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-017-0467-0","volume":"18","author":"Y Pan","year":"2018","unstructured":"Pan, Y., Liu, G., Zhou, F., Su, B. & Li, Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin. Exp. Med. 18 (1), 1\u201314 (2018).","journal-title":"Clin. Exp. Med."},{"issue":"7","key":"20263_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","volume":"30","author":"KD Rasmussen","year":"2016","unstructured":"Rasmussen, K. D. & Helin, K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 30 (7), 733\u2013750 (2016).","journal-title":"Genes Dev."},{"issue":"5","key":"20263_CR22","doi-asserted-by":"publisher","first-page":"e0267946","DOI":"10.1371\/journal.pone.0267946","volume":"17","author":"A Sasaki","year":"2022","unstructured":"Sasaki, A., Murphy, K. E., Briollais, L., McGowan, P. O. & Matthews, S. G. DNA methylation profiles in the blood of newborn term infants born to mothers with obesity. PLoS One. 17 (5), e0267946 (2022).","journal-title":"PLoS One"},{"issue":"1","key":"20263_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12920-017-0248-3","volume":"10","author":"WC de Vega","year":"2017","unstructured":"de Vega, W. C., Herrera, S., Vernon, S. D. & McGowan, P. O. Epigenetic modifications and glucocorticoid sensitivity in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). BMC Med. Genomics. 10 (1), 11 (2017).","journal-title":"BMC Med. Genomics"},{"key":"20263_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.02.006","volume":"65","author":"SM Lim","year":"2018","unstructured":"Lim, S. M., Syn, N. L., Cho, B. C. & Soo, R. A. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat. Rev. 65, 1\u201310 (2018).","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"20263_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41571-018-0004-4","volume":"15","author":"A Koch","year":"2018","unstructured":"Koch, A. et al. Analysis of DNA methylation in cancer: location revisited. Nat. Rev. Clin. Oncol. 15 (7), 459\u2013466 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"20263_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.molcel.2014.08.026","volume":"56","author":"GC Hon","year":"2014","unstructured":"Hon, G. C. et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol. Cell. 56 (2), 286\u2013297 (2014).","journal-title":"Mol. Cell."},{"issue":"8","key":"20263_CR27","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.3390\/curroncol29080451","volume":"29","author":"L Cao","year":"2022","unstructured":"Cao, L. et al. Detection of potential mutated genes associated with common immunotherapy biomarkers in Non-Small-Cell lung cancer patients. Curr. Oncol. 29 (8), 5715\u20135730 (2022).","journal-title":"Curr. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20263-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:38:32Z","timestamp":1760711912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20263-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20263-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36324"}}